Bio-Thera(688177)2024-04-29 09:22Financial Performance - The company's operating revenue for Q1 2024 was RMB 161,591,937.51, representing a year-on-year increase of 4.30%[26] - The net profit attributable to shareholders of the listed company for Q1 2024 was a loss of RMB 118,958,055.48[26] - The net profit attributable to shareholders after deducting non-recurring gains and losses was a loss of RMB 122,773,183.58[26] - The basic and diluted earnings per share for Q1 2024 were both -0.29 RMB[26] - The weighted average return on net assets for Q1 2024 was -10.32%[26] - Total operating revenue for Q1 2024 was 154.93 million in Q1 2023[41] - Net profit for Q1 2024 was a loss of 142.58 million in Q1 2023[42] - Basic and diluted earnings per share for Q1 2024 were both -0.29, compared to -0.34 in Q1 2023[44] - The company's net loss for the period was CNY -119,035,070.61, an improvement from CNY -143,294,729.60 in the previous period[55] - The company reported a net loss of CNY 118,895,169.25 for Q1 2024, an improvement from a net loss of CNY 140,205,070.68 in Q1 2023[82] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 7,352[17] - The largest shareholder, Guangzhou Qixi Group Co., Ltd., held 38.64% of the shares, totaling 159,990,270 shares[17] - Therabio International Limited, the second-largest shareholder, held 11.39% of the shares, totaling 47,177,729 shares[17] - The company has not reported any significant changes in the top 10 shareholders due to margin trading or securities lending[21] Cash Flow and Liquidity - The net cash flow from operating activities for Q1 2024 was a negative RMB 64,803,155.03[26] - Net cash flow from operating activities increased due to higher cash received from sales of goods and services[28] - Cash and cash equivalents increased to ¥341,977,265.74 from ¥163,986,759.82, reflecting improved liquidity[36] - Cash and cash equivalents at the end of Q1 2024 totaled 357.78 million at the end of Q1 2023[48] - The net cash flow from financing activities in Q1 2024 was 248.69 million in Q1 2023[48] - Cash inflow from operating activities for Q1 2024 was 186,026,836.36 in Q1 2023[85] - Net cash flow from operating activities for Q1 2024 was -145,550,657.10 in Q1 2023[85] Research and Development - Total R&D investment amounted to ¥171,622,215.16, a decrease of 25.71%[27] - R&D investment as a percentage of operating revenue decreased by 42.90 percentage points to 106.21%[27] - Research and development expenses were 231.02 million in Q1 2023[41] - Research and development expenses for Q1 2024 were CNY 173,059,632.30, down from CNY 233,112,801.12 in Q1 2023, a decrease of approximately 25.8%[82] - The company plans to continue focusing on R&D and market expansion strategies in the upcoming quarters[41] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,259,221,078.96, down 1.22% from the previous year[27] - Total assets as of Q1 2024 were 2.29 billion in Q1 2023[52] - Total liabilities increased to CNY 1,164,943,634.68, up from CNY 1,073,907,031.98, representing a growth of approximately 8.1%[53] - The total owner's equity decreased to CNY 1,095,160,786.70 from CNY 1,214,195,857.31, reflecting a decline of about 9.8%[53] - The company's retained earnings showed a negative balance of CNY -2,351,443,995.19, worsening from CNY -2,232,408,924.58[53] - The total assets decreased slightly to CNY 2,259,221,078.96 from CNY 2,287,097,856.78, a decline of about 1.2%[64] - Total liabilities and shareholders' equity as of March 31, 2024, were CNY 2,260,104,421.38, a slight decrease from CNY 2,288,102,889.29 at the end of 2023[76] Operational Efficiency - Total operating costs decreased to 323.39 million in Q1 2023, representing a reduction of 12.1%[41] - The company reported a decrease in sales expenses to 41.04 million in Q1 2023[41] - Cash outflow for purchasing fixed assets and intangible assets in Q1 2024 was 92,098,312.72 in Q1 2023[85]